Biogen, HTC, Boston, MIT, Mary Bono: Intellectual Property

March 20 (Bloomberg) -- Biogen Idec Inc., the fourth-largest U.S. biotechnology company by market value, won a U.S. patent that may guard its experimental multiple sclerosis pill from generic competition for eight more years than anticipated.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.